Dupilumab‐Associated Ocular Surface Disease in Pediatric Atopic Dermatitis: A Single‐Center Asian Experience
Pediatric Dermatology · 2025
DOI: 10.1111/pde.15814 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Dermatology, 2025. Verfasst von Amanda Xin Yi Yap und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Service, Department of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore, Singapore. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Eye Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder presenting in childhood. Dupilumab is the first approved biologic agent for the treatment of moderate‐to‐severe AD in pediatric populations. While generally well‐tolerated, dupilumab‐associated ocular surface disease (DAOSD) is a known complication. In severe cases, this may necessitate discontinuation of treatment.
Objective
We aim to describe DAOSD in our cohort of Asian pediatric patients with moderate‐to‐severe AD on dupilumab.
Methods
We performed a single‐center retrospective review of children and adolescents on dupilumab for moderate‐to‐severe AD who developed ophthalmological complications from 2019 to 2024. Most patients had prophylactic lubricant eyedrops. Data collected and analyzed included demographics, ophthalmologic findings, treatment, and outcomes of eye condition.
Results
Of 216 patients treated with dupilumab, 16 (7.4%) developed ophthalmologist‐diagnosed DAOSD. All patients had co‐existing eyelid or head and neck eczema while 31.3% of these patients had pre‐existing eye conditions. Eye redness (87.5%) was the most common presenting symptom, followed by pruritus (43.8%) and eye discharge (25%). The most common eye finding was conjunctivitis (87.5%), followed by limbitis (62.5%) and papillary reaction (62.5%). Two patients required temporary interruption of dupilumab. No patients required discontinuation of dupilumab treatment. The median time to resolution of eye complications was 14 weeks.
Conclusion
In a real‐world setting, the incidence and severity of DAOSD in pediatric patients appears to be lower than that of adults. Prophylactic use of lubricant eye drops, close monitoring and early referral to pediatric ophthalmologists can help reduce the incidence of severe eye disease requiring discontinuation of dupilumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Service, Department of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore, Singapore.
- KK Eye Centre, KK Women's and Children's Hospital, Singapore, Singapore.
- Singapore National Eye Centre, Singapore, Singapore.
- Department of Dermatology, KK Women's and Children's Hospital, Singapore, Singapore.
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
ORCID-Profile: Amanda Xin Yi Yap, Deborah Tan, Mark Jean-Aan Koh, Lin Yi Yang, Koh Yi Zhe, Lynette Wei-Yi Wee
Zitieren
APA
Yap, A. X. Y., Tan, D., Koh, M. J., Yang, L. Y., Zhe, K. Y., & Wee, L. W. (2025). Dupilumab‐Associated Ocular Surface Disease in Pediatric Atopic Dermatitis: A Single‐Center Asian Experience. Pediatric Dermatology. https://doi.org/10.1111/pde.15814
Vancouver
Yap AXY, Tan D, Koh MJ, Yang LY, Zhe KY, Wee LW. Dupilumab‐Associated Ocular Surface Disease in Pediatric Atopic Dermatitis: A Single‐Center Asian Experience. Pediatric Dermatology. 2025. doi:10.1111/pde.15814
BibTeX
@article{Yap2025,
author = {Yap, Amanda Xin Yi and Tan, Deborah and Koh, Mark Jean-Aan and Yang, Lin Yi and Zhe, Koh Yi and Wee, Lynette Wei-Yi},
title = {Dupilumab‐Associated Ocular Surface Disease in Pediatric Atopic Dermatitis: A Single‐Center Asian Experience},
journal = {Pediatric Dermatology},
year = {2025},
doi = {10.1111/pde.15814}
}
EUVIMED